Humalog, Insulin Lispro Newswire

Humalog, Insulin Lispro Newswire

Comprehensive Real-Time News Feed for Humalog, Insulin Lispro (generic).

Results 1 - 20 of 162 in Humalog, Insulin Lispro (generic)

  1. FDA Approves Sanofi's AdmelogRead the original story w/Photo

    Tuesday Dec 12 | Contract Pharma Breaking News

    The U.S. Food and Drug Administration has approved Sanofi 's Admelog, which is the first follow-on insulin lispro to help people living with diabetes manage blood sugar levels at mealtime. "Sanofi has a deep heritage and broad experience in providing treatments for people living with diabetes.

    Comment?

  2. FDA approves admelog for diabetesRead the original story w/Photo

    Tuesday Dec 12 | PhysOrg Weblog

    Admelog , a short-acting form of insulin, has been approved by the U.S. Food and Drug Administration to treat patients aged 3 years and older with either type of diabetes. Admelog is the first drug approved as a follow-up product based on an abbreviated new process dubbed 505 , the agency said Monday in a news release.

    Comment?

  3. FDA Approves Sanofi's Admelog, the First Follow-On Insulin to Control Sugar at MealtimeRead the original story w/Photo

    Monday Dec 11 | BioSpace

    The U.S. Food and Drug Administration has approved Sanofi's AdmelogA , the first follow-on insulin lispro to help people living with diabetes manage blood sugar levels at mealtime. "Sanofi has a deep heritage and broad experience in providing treatments for people living with diabetes.

    Comment?

  4. Sanofi Investors Crave for a Large Acquisition, Drug NewsRead the original story w/Photo

    Monday Dec 11 | BioSpace

    As Sanofi grapples with the fallout from its Dengue vaccine, the termination of its late-stage C. diff vaccine and falling short of its third quarter expectations, company investors are getting antsy for some good news . On Wednesday, Sanofi will hold an Innovation Day to discuss its pipeline with investors.

    Comment?

  5. First short-acting 'follow-on' insulin receives FDA approval to treat diabetesRead the original story w/Photo

    Monday Dec 11 | Medical News

    The U.S. Food and Drug Administration today approved Admelog , a short-acting insulin indicated to improve control in blood sugar levels in adults and pediatric patients aged 3 years and older with type 1 diabetes mellitus and adults with type 2 diabetes mellitus. Admelog is the first short-acting insulin approved as a "follow-on" product pathway).

    Comment?

  6. New Diabetes Drug Gets Fda Ok Under 'Abbreviated' PathwayRead the original story

    Monday Dec 11 | HON

    Admelog , a short-acting form of insulin, has been approved by the U.S. Food and Drug Administration to treat people with either type of diabetes, for patients aged three years and older. It's the first drug approved as a "follow-up" product based on an abbreviated new process dubbed 505 , the agency said Monday in a news release.

    Comment?

  7. FDA Approves Admelog (insulin lispro) Short-Acting 'Follow-On' Insulin Product to Treat DiabetesRead the original story w/Photo

    Monday Dec 11 | Drugs.com

    December 11, 2017 -- The U.S. Food and Drug Administration today approved Admelog , a short-acting insulin indicated to improve control in blood sugar levels in adults and pediatric patients aged 3 years and older with type 1 diabetes mellitus and adults with type 2 diabetes mellitus. Admelog is the first short-acting insulin approved as a "follow-on" product pathway).

    Comment?

  8. FDA clears Sanofi's follow-on diabetes biologic of Lilly's HumalogRead the original story

    Monday Dec 11 | Reuters

    The U.S. Food and Drug Administration said on Monday it approved Sanofi SA's Admelog as the first follow-on biologic version of Eli Lilly and Co's fast-acting insulin, Humalog. FILE PHOTO: French multinational pharmaceutical company SANOFI logo seen at their headquaters in Paris, France, March 8, 2016.

    Comment?

  9. FDA approves Sanofi's rapid-acting insulin analog Admelog; shares up 1%Read the original story w/Photo

    Monday Dec 11 | Seeking Alpha

    The FDA grants full approval for Sanofi's Admelog , a rapid-acting human insulin analog to improve glycemic control in adults and children with diabetes. The agency tentatively approved the product in September under the abbreviated 505 pathway which allows the inclusion of data generated by others.

    Comment?

  10. FDA Approves Sanofi's AdmelogRead the original story

    Monday Dec 11 | GlobeNewswire

    FDA Approves Sanofi's AdmelogA First FDA-approved follow-on mealtime insulin Admelog 100 Units/mL will be available in U.S. in vial and SoloStar pen Paris, France - December 11, 2017 - The U.S. Food and Drug Administration has approved Sanofi's AdmelogA , the first follow-on insulin lispro to help people living with diabetes manage blood sugar levels at mealtime. "Sanofi has a deep heritage and broad experience in providing treatments for people living with diabetes.

    Comment?

  11. Beyond the Planet of the Pharma BrosRead the original story w/Photo

    Tuesday Nov 28 | The American Prospect

    Less a pharma bro than a pharma granddad, Tom Price invested in drug makers while serving as their loyal guard dog in Congress, where he ferociously protected their public funding and bloated profit margins against regulation threats. By nominating the pharmaceutical executive Alex Azar to succeed Price, the administration has accomplished a difficult feat, offering up an even purer embodiment of market-based health care than Price.

    Comment?

  12. Eli Lilly Quietly Works on Wearable Devices in Lab Established in 2015Read the original story w/Photo

    Tuesday Nov 21 | BioSpace

    Eli Lilly continues to make investments in its diabetes business . Not only has the pharma giant devoted millions of dollars to expanding its insulin manufacturing capabilities, the company is also focused on insulin delivery devices.

    Comment?

  13. Alex Azar, Trump's HHS Pick, Has Already Been a Disaster for People with DiabetesRead the original story

    Tuesday Nov 21 | The Nation

    The Nation is reader supported: Chip in $10 or more to help us continue to write about the issues that matter. Last year The New York Times published an op-ed urging the break up of the "insulin racket."

    Comment?

  14. The PNPLA3 I148M variant is associated with transaminase elevations...Read the original story

    Tuesday Nov 21 | The Pharmacogenomics Journal

    Thank you for visiting nature.com. You are using a browser version with limited support for CSS.

    Comment?

  15. Contribution of the dawn phenomenon to the fasting and postbreakfast...Read the original story

    Monday Nov 20 | CiteULike

    Contribution of the dawn phenomenon to the fasting and postbreakfast hyperglycemia in type 1 diabetes treated with once-nightly insulin glargine. To insert individual citation into a bibliography in a word-processor, select your preferred citation style below and drag-and-drop it into the document.

    Comment?

  16. Adocia Reports Topline Results of BioChaperone Glucagon Phase 1 StudyRead the original story w/Photo

    Monday Nov 20 | Business Wire

    BioChaperone Glucagon, a ready-to-inject stable aqueous formulation of human glucagon, was found to be safe and well tolerated in people with type 1 diabetes ADOCIA a clinical stage biopharmaceutical company focused on diabetes treatment with innovative formulations of approved proteins, today announced top-line results of a Phase 1 study of BioChaperoneA Glucagon, its aqueous formulation of human glucagon. The proprietary BioChaperone technology enables solubilization and stabilization of human glucagon at neutral pH.

    Comment?

  17. McCain Warns Trump: No More Industry Insiders in PentagonRead the original story w/Photo

    Friday Nov 17 | The New York Observer

    During a hearing on Thursday, Sens. John McCain and Elizabeth Warren launched a futile investigation into John Rood, head of international sales at Lockheed Martin and Trump's top pick for the Pentagon's no. 3 job, to determine if he would be able to separate himself from business ties if appointed as Under Secretary of Defense for Policy.

    Comment?

  18. Pumping It Up: New Advancements in Insulin DeliveryRead the original story w/Photo

    Friday Nov 17 | US Pharmacist

    ABSTRACT: Continuous subcutaneous insulin infusion devices, commonly referred to as insulin pumps, are a growing trend in diabetes care. Insulin pumps enable patients to program basal delivery of insulin per hour, as well as deliver boluses for food intake throughout the day.

    Comment?

  19. Trump's pick to lower drug prices is a former pharma executive who raised themRead the original story w/Photo

    Nov 13, 2017 | The Washington Post

    Alex Azar meets reporters in 2006, when he served as Deputy Health and Human Services Secretary. President Trump's pick for health secretary previously served as a high-ranking executive at a pharmaceutical company that repeatedly hiked the prices of its drugs, doubling the U.S. list price of its top-selling insulin over the five years he served as a company president.

    Comment?

  20. Medical Affairs Reputations: Type 2 Diabetes MellitusRead the original story w/Photo

    Nov 9, 2017 | PR Newswire

    Medical affairs teams for several leading T2DM treatments in the US seem to be ticking all the boxes in terms of interaction quality. Notwithstanding this, the diabetologists and primary care physicians we surveyed gave mixed views in terms of performance and satisfaction ratings; while some teams standout, others need to up their game.

    Comment?